Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Gilead Loses Patent Fight in China for Pricey Hep C Drug

publication date: Jun 19, 2015
China withdrew one of Gilead Sciences' patents for Sovaldi, its very expensive (and very effective) treatment for hepatitis C. Gilead charges $1,000 per Solvaldi pill ($84,000 for a twelve-week regimen). China rejected the patent on the Solvaldi prodrug, which becomes the chemically active drug in the patient's stomach. Gilead, however, continues to own IP on the active substance. In a similar case two years ago with Viread, an HIV treatment, Gilead released its patent to a pool, allowing generic copies, one year after it lost a patent fight, even though it still had other active patents. More details....

Stock Symbol: (NSDQ: GILD)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital